Vimarsana
Biggest News Aggregation in the World

Page 10 - Late Stage Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Late Stage Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Late Stage Development Today - Breaking & Trending Today

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control - Vimarsana News

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

Adaptimmune Therapeutics plc , a leader in cell therapy to treat cancer, to present outcome data from Cohort 1 of its pivotal SPEARHEAD-1 trial at the Connective Tissue Oncology Society annual...

Novel Agents Highlight Changes in Myeloma Field - Vimarsana News

Novel Agents Highlight Changes in Myeloma Field

Leading investigators in the multiple myeloma field discuss the latest clinical trial findings, many of which were presented during the 2023 ASCO Annual Meeting.

Adaptimmune Therapeutics PLC: Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO - Vimarsana News

Adaptimmune Therapeutics PLC: Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO

Approximately 39% of patients had clinical responses after a single dose of afami-cel in Cohort 1 of the pivotal SPEARHEAD-1 trial and the median duration of response was ~12 months (CTOS 2022)Median

Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology - Vimarsana News

Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology

- Data presentations demonstrate continued potential of PADCEV® (enfortumab vedotin-ejfv) in multiple types of urothelial cancer -- Patient-reported outcomes underscore Seagen’s commitment to addressing patients’ needs and quality of life -BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced t...

Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma - Vimarsana News

Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

10.11.2022 - Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) for the treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin ... Seite 1